Presentation is loading. Please wait.

Presentation is loading. Please wait.

Concomitant Atrial Fibrillation - allways Maze? - Robert JM Klautz chief department Cardiothoracic Surgery.

Published bySimon Collins Modified over 9 years ago

Similar presentations

Presentation on theme: "Concomitant Atrial Fibrillation - allways Maze? - Robert JM Klautz chief department Cardiothoracic Surgery."— Presentation transcript:

1 Concomitant Atrial Fibrillation - allways Maze? - Robert JM Klautz chief department Cardiothoracic Surgery

2 Get Rhythm 2006

3 Questions What do we want to achieve?What do we want to achieve? SRSR reduce need for OAC / AADreduce need for OAC / AAD freedom from palpitationsfreedom from palpitations freedom from TE / strokefreedom from TE / stroke improve LV functionimprove LV function What is achieved by the primary procedure?What is achieved by the primary procedure? Which patients benefit, what is the price?Which patients benefit, what is the price?

4 Concomitant AF definitiondefinition AF in a patient undergoing cardiac surgeryAF in a patient undergoing cardiac surgery Type of SurgeryType of Surgery Mitral valve surgeryMitral valve surgery Aortic valve surgeryAortic valve surgery CABGCABG Type of AFType of AF paroxysmalparoxysmal persistentpersistent permanentpermanent

5 Bleeding Risk with Warfarin Major Haemorrhage 4.6% /yrMajor Haemorrhage 4.6% /yr hospitalization, transfusion, or surgeryhospitalization, transfusion, or surgery Chimowitz et al NEJM 2005 ICH risk: 0.1% /yr no AC RR AC 0.5% disabilty doubled ICH risk: 0.1% /yr no AC RR AC 0.5% disabilty doubled

6 Prevalence of Preoperative AF - likelyhood of concomitant treatment - STS database 2004-2006 Gammi et al Ann Thor Surg 2008

7 AF in Mitral Valve Disease - prevalence - AF in medically treated MV disease: linearized rate 5% per year ! AF in medically treated MV disease: linearized rate 5% per year ! Grigioni et al JACC 2002

8 AF in Mitral Valve Disease - risk - Grigioni et al JACC 2002 AF is an independent risk factor for death in MR patients

9 Survival after Mitral Valve Surgery - pre-operative SR vs AF - Ngaage et al Ann Thorac Surg 2004

10 If AF is a risk factor for bad outcome in MV disease and after MV surgery Can we modify it ? If AF is a risk factor for bad outcome in MV disease and after MV surgery Can we modify it ?

11 Cox Maze III + MV surgery Remains gold standard regarding lesion set Superior freedom from AfibMCT + RCT ? 80 % at 5 years Superior freedom from Stroke / TEMCT (trend in RCT) No survival benefit (yet) But: obsolete Combined MV & AF Surgery Wong et al Ann Thorac Surg 2006

12 MV surgery and AF intervention RCT 6 mo AFRCT 6 mo AF 24 MV repair + Biatrial modRF24 MV repair + Biatrial modRF 25 MV repair + intensive rhythm control25 MV repair + intensive rhythm control von Oppell et al. Eur J CardioThor Surg 2009 63% of pts with SR after AF-ablation had normal atrial function63% of pts with SR after AF-ablation had normal atrial function

13 RadiofrequencyRadiofrequency Dry / IrrigatedDry / Irrigated Unipolar / BipolarUnipolar / Bipolar CryothermiaCryothermia High Frequency UltrasoundHigh Frequency Ultrasound MicrowaveMicrowave LaserLaser Combined MV & AF Surgery - new energy sources -

14 Electrophysiological Goals in AF Surgery What do we aim for? Conduction block Eliminate triggers/foci PV isolation (complex or box) Reduce substrate Connecting line roof LA Mitral isthmus line Connecting line roof LA Mitral isthmus line LA RA Intercaval? Free wall? Isthmus ?

15 How to decide on an approach? First: STANDARDIZE Then: INDIVIDUALIZE First: STANDARDIZE Then: INDIVIDUALIZE

16 Lesion sets for AF Surgery Paroxysmal AF: pulmonary vein isolation (PVI) Epicardially closed beating heart, off-pump Energy sourcebipolar RF cryothermia Accessminimal access possible

17 Lesion sets for AF Surgery Persistent / permanent AF: substrate reduction Epicardiallylimited to box lesion only Energy sourceHIFU (ultrasound) (+ mitral isthmus) cryothermia bipolar RF Accessminimal access possible

18 Lesion sets for AF Surgery EndocardiallyFull CM III / “derivative” Energy sourcebipolar RF cryothermia (cut and sew) Accessminimal access possible (CM IV) Persistent / permanent AF: substrate reduction

19 How to standardize - Concomitant AF CONCOMITANT AF: sternotomy in general, minimal access in selected cases paroxysmal cases: PVI only (off-pump) persistent cases: more extensive lesions – epi-endocardial

20 How to standardize - Concomitant AF - extended pulmonary vein isolation - Benussi et al J Thorac Cardiovasc Surg 2005

21 How to standardize - Concomitant AF - mitral isthmus line - Benussi et al J Thorac Cardiovasc Surg 2005

22 How to standardize - Concomitant AF CONCOMITANT AF: Trade off: -Quite invasive for aortic valve or CABG procedures Question: -Right sided lesions ?

23 How to standardize - Concomitant AF - right sided lesions - Barnett et al J Thorac Cardiovasc Surg 2006

24 How to standardize - Concomitant AF - right sided lesions - PM implantation rate not studied Barnett et al J Thorac Cardiovasc Surg 2006

25 How to standardize - Concomitant AF - right sided lesions - "Addition of right atrial lesions conferred no additional benefit in these patients" "…both the left atrial combined with cavotricuspid isthmus ablation and biatrial procedures had similar outcomes despite significant shorter CPB times in the LA group"

26 Combined MV & AF Surgery - Left Atrial Appendage - Garcia-Fernandez et al JACC 2003

27 Combined MV & AF Surgery - Left Atrial Appendage - Retrospective analysis of 205 MV replacement pts 14 % SR 58 ligation LAA (6 incomplete) 69 months: 27 TE events Absence of LAA ligation vs TE: OR 6.7 Including incomplete LAA ligation: OR 11.9 Garcia-Fernandez et al JACC 2003

28 Combined MV & AF Surgery - Left Atrial Appendage - Kanderian et al JACC 2008

29 Combined MV & AF Surgery - Left Atrial Appendage - Kanderian et al JACC 2008

30 LAA Closure - Watchman Device - Holmes et al Lancet 2009

31 Atrioventricular Block – PM implantationAtrioventricular Block – PM implantation Collateral DamageCollateral Damage Lesions related tachy-arrythmiasLesions related tachy-arrythmias Surgery for Atrial Fibrillation - inherent risks -

32 ESC Guideline AF 2010

33 Concomitant AF Surgery - the future - Patient-specific approachPatient-specific approach Assessment of conduction blockAssessment of conduction block Team up with EP cardiologistTeam up with EP cardiologist TrialsTrials CRAFT-CABGCRAFT-CABG

34 Allways Maze? Fewer lesionsFewer lesions Patients with paroxysmal AF: PVIPatients with paroxysmal AF: PVI LAALAA No ablationNo ablation low chance of succeslow chance of succes large atrium, (very) long standinglarge atrium, (very) long standing high riskhigh risk elderly patientelderly patient

Download ppt "Concomitant Atrial Fibrillation - allways Maze? - Robert JM Klautz chief department Cardiothoracic Surgery."

Similar presentations

AF ablation with 3D mapping: our technique and results

AF ablation with 3D mapping: our technique and results
Ali Alsayegh, MD, FRCPC,FACC Consultant Cardiologist, Consultant Cardiac Electrophysiologist.

Ali Alsayegh, MD, FRCPC,FACC Consultant Cardiologist, Consultant Cardiac Electrophysiologist.
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)

Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
The Maze Procedure in Mitral Vale Disease Ki-Bong Kim, MD Dept. of Thoracic & Cardiovascular Surgery Seoul National University Hospital.

The Maze Procedure in Mitral Vale Disease Ki-Bong Kim, MD Dept. of Thoracic & Cardiovascular Surgery Seoul National University Hospital.
The Future of Minimally Invasive Cardiac Surgery Marco A. Zenati, M.D. Professor of Surgery and Bioengineering University of Pittsburgh School of Medicine.

The Future of Minimally Invasive Cardiac Surgery Marco A. Zenati, M.D. Professor of Surgery and Bioengineering University of Pittsburgh School of Medicine.
1/ Incidence of AF: 5% of the population > 60 years, - 600 000 candidates for AF surgery in USA 2/ Etiologies: among patients applying for a life insurance:

1/ Incidence of AF: 5% of the population > 60 years, candidates for AF surgery in USA 2/ Etiologies: among patients applying for a life insurance:
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Radiofrequency Maze Operation for Permanent Atrial Fibrillation

Radiofrequency Maze Operation for Permanent Atrial Fibrillation
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
INTERVENTIONAL TREATMENT OF ATRIAL FIBRILLATION St. Mary’s Hospital February – August 2007.

INTERVENTIONAL TREATMENT OF ATRIAL FIBRILLATION St. Mary’s Hospital February – August 2007.
Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary’s University of London.

Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary’s University of London.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
John R Onufer MD FHRS.  Paroxysmal(that which terminates spontaneously) Persistent Sustained > 7 days, or lasting < 7 days but requires pharmacologic.

John R Onufer MD FHRS.  Paroxysmal(that which terminates spontaneously) Persistent Sustained > 7 days, or lasting < 7 days but requires pharmacologic.
Audit of ablation procedures for AF Barts and The London.

Audit of ablation procedures for AF Barts and The London.
Dubrava University Hospital Zagreb, Croatia www.kbd.hr DEPARTMENT OF CARDIAC SURGERY RF Ablation of Atrial Fibrillation in Valvular Heart Surgery Patients.

Dubrava University Hospital Zagreb, Croatia DEPARTMENT OF CARDIAC SURGERY RF Ablation of Atrial Fibrillation in Valvular Heart Surgery Patients.
Late outcomes of the Cox-Maze IV procedure for atrial fibrillation Matthew C. Henn MD, Timothy S. Lancaster MD, Jacob R. Miller MD, Laurie A. Sinn RN,

Late outcomes of the Cox-Maze IV procedure for atrial fibrillation Matthew C. Henn MD, Timothy S. Lancaster MD, Jacob R. Miller MD, Laurie A. Sinn RN,
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Catheter Ablation of Atrial Fibrillation: Who? How? How Good? John D. Day, M.D. Director, Utah Cardiovascular Research Institute Utah Heart Clinic Arrhythmia.

Catheter Ablation of Atrial Fibrillation: Who? How? How Good? John D. Day, M.D. Director, Utah Cardiovascular Research Institute Utah Heart Clinic Arrhythmia.
AF: Catheter Ablation Isolation of the 4 pulmonary veins Linear lesions to create additional lines of block 1.

AF: Catheter Ablation Isolation of the 4 pulmonary veins Linear lesions to create additional lines of block 1.

Similar presentations

Ads by Google